Clinical Trial Update: A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) [Phase 2]

View source ↗

Summary

Phase 2 trial of PF-06730512 in adults with focal segmental glomerulosclerosis (FSGS) was terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• PF-06730512

Snippet

Sponsor: Pfizer | Conditions: Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 | Status: TERMINATED | Results posted: 2024-04-18